| MUTHU RAJA, Karthick Raja, Martin PLÁŠIL, Lucie ŘÍHOVÁ, Jana PELCOVÁ, Zdeněk ADAM and Roman HÁJEK. Flow Cytometry-Based Enumeration and Functional Characterization of CD8 T Regulatory Cells in Patients with Multiple Myeloma Before and After Lenalidomide Plus Dexamethasone Treatment (Flow Cytometry-Based Enumeration and Functional Characterization of CD8 T Regulatory Cells in Patients with Multiple Myeloma Before and After Lenalidomide Plus Dexamethasone treatment). Cytometry Part B ( Clinical cytometry). HOBOKEN: WILEY-BLACKWELL, 2014, vol. 86, No 4, p. 220-228. ISSN 1552-4949. doi:10.1002/cyto.b.21109. |
Other formats:
BibTeX
LaTeX
RIS
@article{1127615,
author = {Muthu Raja, Karthick Raja and Plášil, Martin and Říhová, Lucie and Pelcová, Jana and Adam, Zdeněk and Hájek, Roman},
article_location = {HOBOKEN},
article_number = {4},
doi = {http://dx.doi.org/10.1002/cyto.b.21109},
keywords = {CD8 T regulatory cells; multiple myeloma; immune suppression; lenalidomide; dexamethasone; flow cytometry and CFSE},
language = {eng},
issn = {1552-4949},
journal = {Cytometry Part B ( Clinical cytometry)},
title = {Flow Cytometry-Based Enumeration and Functional Characterization of CD8 T Regulatory Cells in Patients with Multiple Myeloma Before and After Lenalidomide Plus Dexamethasone Treatment},
volume = {86},
year = {2014}
}
TY - JOUR
ID - 1127615
AU - Muthu Raja, Karthick Raja - Plášil, Martin - Říhová, Lucie - Pelcová, Jana - Adam, Zdeněk - Hájek, Roman
PY - 2014
TI - Flow Cytometry-Based Enumeration and Functional Characterization of CD8 T Regulatory Cells in Patients with Multiple Myeloma Before and After Lenalidomide Plus Dexamethasone Treatment
JF - Cytometry Part B ( Clinical cytometry)
VL - 86
IS - 4
SP - 220-228
EP - 220-228
PB - WILEY-BLACKWELL
SN - 15524949
KW - CD8 T regulatory cells
KW - multiple myeloma
KW - immune suppression
KW - lenalidomide
KW - dexamethasone
KW - flow cytometry and CFSE
N2 - Background: Multiple myeloma (MM) is a malignancy of plasma cells frequently associated with immune abnormalities. Several studies have confirmed that in MM immune deregulation can be mediated by increased numbers of CD4 T regulatory (Treg) cells, and these cells were also associated with poor outcome. In this study, we aimed to study CD8 Treg cells before and after lenalidomide plus dexamethasone (len-dex) treatment in MM patients. Methods: Using flow cytometry, we enumerated and assessed suppressive function of CD8 Treg cells in 16 MM patients before and after len-dex treatment. Results: Numbers of CD8 Treg cells (CD8+CD25hi+FoxP3+) (P < 0.01) were significantly increased in MM patients (before treatment) compared to healthy donors. However, no significant changes were observed in CD4 and CD8 T cells. A significant increase in CD8 Treg cells was observed after len-dex treatment compared to pre-treatment but no significant difference was observed in CD4 and CD8 T cells. Proliferation assay data showed that CD8 Treg cells inhibited proliferation of CD4 T cells and IFN-gamma secretion in a concentration dependent manner. Suppressive activity of CD8 Treg cells did not differ significantly between healthy donors, untreated and len-dex treated MM patients. A significant abnormal level of IL-10 was observed from proliferation assays of untreated and len-dex treated MM patients compared to healthy donors (P <= 0.03). Conclusions: Using flow cytometry, we have shown that suppressive CD8 Treg cells are increased in MM patients and len-dex treatment is unable to control these suppressive CD8 Treg cells. (C) 2013 International Clinical Cytometry Society
ER -
MUTHU RAJA, Karthick Raja, Martin PLÁŠIL, Lucie ŘÍHOVÁ, Jana PELCOVÁ, Zdeněk ADAM and Roman HÁJEK. Flow Cytometry-Based Enumeration and Functional Characterization of CD8 T Regulatory Cells in Patients with Multiple Myeloma Before and After Lenalidomide Plus Dexamethasone Treatment (Flow Cytometry-Based Enumeration and Functional Characterization of CD8 T Regulatory Cells in Patients with Multiple Myeloma Before and After Lenalidomide Plus Dexamethasone treatment). \textit{Cytometry Part B ( Clinical cytometry)}. HOBOKEN: WILEY-BLACKWELL, 2014, vol.~86, No~4, p.~220-228. ISSN~1552-4949. doi:10.1002/cyto.b.21109.
|
